EUVIMEDOpdag EUVIMED
FallberichtStudienprotokollOpen access · CC BY 4.0

First successful protocol for desensitization to eptinezumab

Benoit Gerard, Hubert Praudel, Michel Lanteri-Minet, Elise Van Obberghen, Fanny Rocher-Moreau, Johanna Rousset, Ulysse Jacquier, Sylvie Leroy, Margot Delin iD

Headache: The Journal of Head and Face Pain · 2026

DOI: 10.1111/head.70000 ↗

At a glance

Fallbericht in Headache: The Journal of Head and Face Pain, 2026. Written by Benoit Gerard and 8 co-authors. Institution: Département de pneumologie et d'oncologie thoracique, Centre Hospitalier Universitaire de Nice, IHU RespirERA, Université Côte d'Azur, Nice, France. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Desensitization, Immunologic, Migraine Disorders, Drug Hypersensitivity. 9 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Eptinezumab is an anti‐calcitonin gene‐related peptide monoclonal antibody used for migraine prevention. During clinical trials, hypersensitivity to eptinezumab was described without a clear underlying mechanism. To determine if the reaction was immunoglobulin E–mediated, the team of Nice University Hospital (Nice, France) performed the eptinzeumab skin tests. A 10‐step desensitization protocol has been proposed to manage these reactions.

Findings

Two patients presenting with immediate hypersensitivity reactions underwent the eptinezumab skin test. Neither skin test was positive, suggesting a non‐immunoglobulin E–mediated mechanism. The patients then completed the desensitization protocol successfully.

Conclusion

This hospital‐based 10‐step desensitization protocol appears safe and effective.

Subjects

MeSH terms (MEDLINE)

Antibodies, Monoclonal, HumanizedDesensitization, ImmunologicMigraine DisordersDrug HypersensitivityCalcitonin Gene-Related Peptide Receptor AntagonistsHumansFemaleMaleAdultMiddle AgedSkin Tests

Author keywords

allergydesensitizationeptinezumabskin test

Substances

Antibodies, Monoclonal, HumanizedeptinezumabCalcitonin Gene-Related Peptide Receptor Antagonists

Authors and institutions

  • Département de pneumologie et d'oncologie thoracique, Centre Hospitalier Universitaire de Nice, IHU RespirERA, Université Côte d'Azur, Nice, France.
  • Pain Department, Centre Hospitalier Universitaire de Nice, FHU Inovpain, URC2A, Université Côte d'Azur, Nice, France.
  • INSERM U1107 Migraine and Trigeminal Pain, Auvergne University, Clermont-Ferrand, France.
  • Centre régional de pharmacovigilance, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.

ORCID profiles: Margot Delin

Cite

APA

Gerard, B., Praudel, H., Lanteri-Minet, M., Van Obberghen, E., Rocher-Moreau, F., Rousset, J., Jacquier, U., Leroy, S., & Delin, M. (2026). First successful protocol for desensitization to eptinezumab. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.70000

Vancouver

Gerard B, Praudel H, Lanteri-Minet M, Van Obberghen E, Rocher-Moreau F, Rousset J, et al. First successful protocol for desensitization to eptinezumab. Headache: The Journal of Head and Face Pain. 2026. doi:10.1111/head.70000

BibTeX
@article{Gerard2026,
  author = {Gerard, Benoit and Praudel, Hubert and Lanteri-Minet, Michel and Van Obberghen, Elise and Rocher-Moreau, Fanny and Rousset, Johanna and Jacquier, Ulysse and Leroy, Sylvie and Delin, Margot},
  title = {First successful protocol for desensitization to eptinezumab},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  doi = {10.1111/head.70000}
}
Start for free →